Another study showed that HMGB1, synergistically with ATP, could induce DCs to release interleukin‐1β (IL-1β), and HMGB1-specific antibodies can block the ability of IL-1β production in DCs after exposure to dying tumor cells (32). The gene discussed is HMGB1; the disease is neoplasm.